SCHEMBL5635263

SCHEMBL5635263

O=S(=O)(NN1CCc2ccccc21)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
GAA P10253 4/20 0.51
TP53 P04637 2/20 0.51
HTR7 P34969 3/20 0.49
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TSHR P16473 3/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
PKM P14618 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GFER P55789 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.44
MCOLN2 Q8IZK6 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852381 0.80 NOTUM (0.45) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL5226699 0.80 MEN1 (0.45) MAPTGAATP53ALDH1A1MEN1
SCHEMBL10746811 0.77 MEN1 (0.44) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7785220 0.76 ALDH1A1 (0.44) MAPTGAATP53ALDH1A1MEN1
SCHEMBL7126729 0.75 ALDH1A1 (0.51) MAPTGAATP53ALDH1A1MEN1
SCHEMBL29985725 0.75 ALDH1A1 (0.51) MAPTGAATP53ALDH1A1MEN1
SCHEMBL31311097 0.72 PARL (0.43) HTR7ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL395744 0.71 MEN1 (0.77) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL5120536 0.71 NOTUM (0.50) MAPTGAATP53ALDH1A1MEN1
SCHEMBL29682974 0.71 MEN1 (0.77) MAPTGAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006117075-A1 USE OF INDOLIN-PHENYLSULFONAMIDE DERIVATIVES BAYER HEALTHCARE AG (DE) 2006-11-09 WO disclosed
WO-2006117076-A1 USE OF INDOLIN-PHENYLSULFONAMIDE DERIVATIVES BAYER HEALTHCARE AG (DE) 2006-11-09 WO disclosed
US-20060100230-A1 Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2006-05-11 US disclosed
US-20060100230-A1 Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2006-05-11 US disclosed
US-20060100230-A1 Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2006-05-11 US disclosed
CN-1678581-A Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2005-10-05 CN disclosed
CN-1678581-A Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2005-10-05 CN disclosed
CN-1678581-A Indolin phenylsulfonamide derivatives BAYER HEALTHCARE AG (DE) 2005-10-05 CN disclosed
EP-1519919-A1 INDOLIN PHENYLSULFONAMIDE DERIVATIVES Bayer HealthCare AG (DE) 2005-04-06 EP disclosed
WO-2004005253-A1 INDOLIN PHENYLSULFONAMIDE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100230-A1 Indolin phenylsulfonamide derivatives PPARD, PPARA, PPARG MAPT 4156/4885GAA 2558/4885TP53 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.